CD20, a membrane protein prominently found on B-lymphocytes, is a vital target for monoclonal antibodies in treating various diseases. This study focused on the extraction and purification of native CD20 from different cell lines, unlocking its potential for bioassay development.
Leveraging our proprietary detergent, Eurofins CALIXARene-based detergent approach enhanced CD20 protein yield. This innovative method resulted in non-aggregated CD20 that exhibited concentration-dependent oligomerization. Although specific structural details of CD20 remain elusive, the purified protein was shown to form confined nanodroplets that resist aggregation, which is crucial for maintaining its functionality during experimental procedures.
The purified CD20 demonstrated a significant capacity to bind to therapeutic antibodies such as rituximab and obinutuzumab. This binding capability was confirmed through various techniques, including size exclusion chromatography and surface plasmon resonance. The ability to effectively bind these antibodies offers a promising avenue for advanced bioassay research, paving the way for further investigations into CD20's interactions with newly developed antibodies.
Moreover, the methodology used in this study not only enhances the understanding of CD20 functionality but also holds the potential to be applied to other challenging membrane proteins. By optimizing the extraction and purification processes, researchers can explore the biochemical properties of CD20 more effectively, ultimately leading to improved therapeutic strategies for diseases associated with B-lymphocytes.
In summary, the extraction and purification of native CD20 using our proprietary detergent approach has unlocked new possibilities for bioassay development and therapeutic research, with the potential to extend to other challenging membrane proteins. The findings from this study reinforce the importance of CD20 as a target for monoclonal antibodies and highlight the potential for advancing treatments for various B-cell related diseases.
References :
Morgane A. et al. 2019
